Last Updated: November 8, 2026

DANOCRINE Drug Patent Profile

Name: DANOCRINE Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

Which patents cover Danocrine, and what generic alternatives are available?

Danocrine is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in DANOCRINE is danazol. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the danazol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Danocrine

A generic version of DANOCRINE was approved as danazol by BARR on August 9^th, 1996.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for DANOCRINE?
What are the global sales for DANOCRINE?
What is Average Wholesale Price for DANOCRINE?

Summary for DANOCRINE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	6
Patent Applications:	6,591
DailyMed Link:	DANOCRINE at DailyMed

Drug patent expirations by year for DANOCRINE

Recent Clinical Trials for DANOCRINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sierra Oncology, Inc.	Phase 3
Peking University People's Hospital	Phase 1/Phase 2
Mayo Clinic	Phase 2

See all DANOCRINE clinical trials

US Patents and Regulatory Information for DANOCRINE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	DANOCRINE	danazol	CAPSULE;ORAL	017557-003	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sanofi Aventis Us	DANOCRINE	danazol	CAPSULE;ORAL	017557-004	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sanofi Aventis Us	DANOCRINE	danazol	CAPSULE;ORAL	017557-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.